Anacor
also invests · investor profileAcquiredNew York, US · 7 known investors
Find your way into Anacor
Sign up to see every warm intro you have to Anacor
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Anacor team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pfizer discovers, develops, manufactures, and distributes pharmaceutical medicines and vaccines across therapeutic areas including oncology, cardiology, immunology, and infectious diseases. The company serves patients, healthcare professionals, and consumers globally through its research, development, and commercial operations.
Also known as Anacor Pharmaceuticals · Anacor Pharmaceuticals, Inc.
Founders & leadership
Investors · 7
How we know: Aisling Capital's portfolio page · Not right? Tell us
How we know: Rho Capital Partners's portfolio page · Not right? Tell us
How we know: Rho Ventures's portfolio page · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · Not right? Tell us
How we know: Venrock's portfolio page · funding news · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Company profile
researched Aug 2026Anacor Pharmaceuticals, Inc. was a biopharmaceutical company headquartered in Palo Alto, California, founded in 2002. It discovered, developed and commercialized novel small-molecule therapeutics built on boron-containing chemistry, with programs oriented toward inflammation, immunology, dermatology and infectious disease. The company operated in the pharmaceutical manufacturing sector and, as a small organization, advanced boron-containing compounds from research into clinical development.
Its lead asset was crisaborole, a non-steroidal topical PDE4 inhibitor with anti-inflammatory properties developed for mild-to-moderate atopic dermatitis (eczema). Crisaborole met all primary and secondary endpoints in two Phase 3 pivotal studies, and the FDA accepted Anacor's New Drug Application for review in March 2016, setting a PDUFA goal date of January 7, 2017. Anacor also held rights to Kerydin (tavaborole), a topical treatment for onychomycosis (toenail fungus) distributed and commercialized in the United States by Sandoz Inc.
Anacor traded on the NASDAQ Global Market under the ticker ANAC. In May 2016 Pfizer agreed to acquire the company for $99.25 per share in cash, a total transaction value net of cash of approximately $5.2 billion assuming conversion of Anacor's outstanding convertible notes. The acquisition closed on June 24, 2016, and Anacor became a wholly owned subsidiary of Pfizer.
Business model
Anacor developed proprietary small-molecule drug candidates from its boron chemistry platform, seeking regulatory approval and commercialization; for marketed products such as Kerydin it relied on partners, with Sandoz Inc. distributing and commercializing the product in the United States.
Latest developments
Pfizer announced a definitive merger agreement to acquire Anacor on May 16, 2016 at $99.25 per share in cash, approximately $5.2 billion net of cash. The tender offer expired after 11:59 p.m. New York time on June 23, 2016, with about 86.1% of outstanding shares validly tendered, and Pfizer completed the acquisition through a second-step merger on June 24, 2016, when joint operations began.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Anacor was a small biopharmaceutical company with a differentiated boron-chemistry platform in inflammation and immunology. Pfizer estimated peak-year sales for crisaborole could reach or exceed $2.0 billion, and noted that no new molecular entities had been introduced for atopic dermatitis in the prior 15 years, with approximately 18 to 25 million people in the United States affected by the condition.
Its boron-based chemistry produced small molecules with novel mechanisms of action; crisaborole was positioned as a non-steroidal topical PDE4 inhibitor in a therapeutic area with few safe topical treatment options.
Technology
The company's platform was based on boron-containing chemistry used to create small-molecule therapeutics with differentiated mechanisms of action. Its lead compound crisaborole was a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor with anti-inflammatory properties; Kerydin (tavaborole) was a topical antifungal for onychomycosis.
Go-to-market
Patients with inflammatory skin disease, principally mild-to-moderate atopic dermatitis, and patients with onychomycosis, reached through pediatricians, primary care physicians and dermatologists.
Geography
Headquartered in Palo Alto, California, United States, with commercialization of Kerydin in the U.S. handled by Sandoz Inc.
History
Founded in 2002 in Palo Alto, California, Anacor built a pipeline of boron-containing small molecules. It became a NASDAQ-listed company (ANAC). By March 2016 the FDA had accepted its New Drug Application for crisaborole. In May 2016 it entered into a definitive merger agreement with Pfizer, and the acquisition was completed on June 24, 2016, after which Anacor's shares ceased trading on NASDAQ.
Risks & controversies
As a small company with limited headcount, Anacor depended on external collaborators and partners for development and commercialization; its lead asset crisaborole remained subject to FDA approval at the time of the acquisition.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsThe tender offer expired immediately after 11:59 p.m. New York City time on June 23, 2016, with 39,306,909 shares (approximately 86.1% of outstanding shares) validly tendered. Pfizer completed the acquisition through the merger of Quattro Merger Sub Inc. into Anacor under Section 251(h) of the Delaware General Corporation Law; Anacor became a wholly owned subsidiary and its common stock ceased trading on the NASDAQ Global Market. Joint operations began June 24, 2016.
$5.2B source ↗
Pfizer and Anacor entered into a definitive merger agreement under which Pfizer would acquire Anacor for $99.25 per share in cash, a total transaction value net of cash of approximately $5.2 billion assuming conversion of Anacor's outstanding convertible notes. The offer price represented a 55% premium to Anacor's closing price of $64.03. Both boards unanimously approved the transaction.
$5.2B source ↗
The FDA accepted for review Anacor's New Drug Application seeking approval of crisaborole for mild-to-moderate atopic dermatitis in children and adults, with a PDUFA goal date of January 7, 2017.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 6
primary sources listed
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Anacor do?
- Biopharmaceutical company developing boron-based small-molecule therapeutics for inflammatory and dermatologic disease; acquired by Pfizer in 2016.
- Who founded Anacor?
- Anacor was founded by Charles Pfizer.
- Who are Anacor's investors?
- Anacor's investors include Aisling Capital, Andera Partners, Rho Capital Partners, Rho Ventures, RiverVest Venture Partners, Venrock, New Enterprise Associates (NEA).
- Where is Anacor headquartered?
- Anacor is headquartered in New York, US.


